Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study

Zhen Yang | Guangjun Shi

Department of Hepatopancreatobiliary Surgery, Qingdao Municipal Hospital, Qingdao University, Qingdao, P.R. China

Correspondence
Guangjun Shi, Department of Hepatopancreatobiliary Surgery, Qingdao Municipal Hospital, Qingdao University, No. 5 Donghai Middle Road, Qingdao, 266000, P.R. China. Email: sgjzp@hotmail.com

Abstract

Background: Combined hepatocellular-cholangiocarcinoma (CHC) is a heterogeneous group of primary liver cancers characterized by the coexistence of both hepatic and biliary cellular contents. The aim of this study was to compare CHC and intrahepatic cholangiocarcinoma (ICC) and investigate the treatment and survival of patients with CHC.

Methods: Data on CHC and ICC, including clinicopathological characteristics, treatments, and survival outcomes were extracted from the SEER database between 2004 and 2016. Univariate and multivariate analyses of all data were performed to identify the risk factors associated with survival outcomes. The overall survival (OS) rates of CHC patients who underwent hepatic resection (HR) or liver transplantation (LT) were also assessed before and after propensity score matching.

Results: A total of 1066 consecutive patients who had been diagnosed with CHC (n = 286) or ICC (n = 780) were identified. The mean age of the CHC cohort was 60.8±10.7 years old. Among the CHC group, a large proportion of the patients were men and of White ethnicity (73.1% and 71.3%, respectively). The majority of tumors were poorly differentiated (37.8%), while the most common AJCC stage at presentation was stage I (31.4%). Multivariable analysis of all CHC patients revealed that only tumor size, M1 stage, AJCC stage IIIC, AJCC stage IV, surgery, and chemotherapy were significantly associated with OS. The OS was comparable with the ICC in the initial 36 months and better in the subsequent follow-up after treatment. Surgery was associated with better survival outcomes, whether in the early or advanced stages. Regarding the specific types of surgery, the OS rates were similar in selected patients following HR or LT.

Conclusion: In patients with CHC, surgical intervention resulted in better long-term survival outcomes than nonsurgical treatments. The OS rate of CHC patients compared with that of ICC patients was discriminated before and after a 3-year follow-up.
1 | INTRODUCTION

Combined hepatocellular-cholangiocarcinoma (CHC) is a rare subtype of primary liver cancer with biphenotypic characteristics of both hepatocytic and cholangiocytic differentiation, accounting for 0.4%–14.2% of primary liver malignancies.1–3 As the name implies, CHC was currently viewed as a constitution with the dual clinicopathological features of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).4,5 Due to its rarity and ambiguous biological features of CHC may hinder the formulation of treatment protocols and seriously affect the prognosis of patients. Previous studies have reported that CHC and ICC have comparable survival outcomes.6 Molecular analysis suggested that CHC and ICC shared common altered carcinogenic pathways and were genetically closer compared to HCC,7 while other genomic profiling uncovered genetic similarities between CHC and HCC.8 To date, there have been limited investigations of patients with CHC. As one subtype of the uncommon liver cancers, the demographics, clinical features, survival outcomes, risk factors, and therapeutic landscapes especially the role of radical resection remained largely unknown. Therefore, the purpose of this large population study based on the SEER program was to clearly define the clinicopathologic characteristics and to evaluate the survival outcomes as well as different therapeutic regimens.

2 | PATIENTS AND METHODS

2.1 | Database

Patients pathologically diagnosed with CHC and ICC were identified from the Surveillance, Epidemiology, and End Result cancer database (SEER) between 2004 and 2016. A total of 1066 patients were included in this retrospective study. Of these, 286 patients were confirmed to have CHC and 780 patients had ICC. The data on demographics, American Joint Committee on Cancer (AJCC) stages, histopathological characteristics, treatments, and survival outcomes were collected from the database. The patients with incomplete information regarding the clinical variables were not included.

2.2 | Statistical analysis

Continuous variables were described as means (±SD) or medians (interquartile range) and analyzed using the Student’s t test or the Mann–Whitney U test, as appropriate. Categorical data are shown as number (percentage) and were assessed using the chi-square ($\chi^2$) test or Fisher’s exact test, as appropriate. The overall survival (OS) and cancer-specific survival (CSS) curves were calculated using the Kaplan–Meier method and estimated using the log-rank test. The univariate and multivariate analyses of all data were performed using the Cox proportional hazards regression model. A propensity score matching (PSM) method using logistic regression was utilized to correct the case-mix in order to overcome the selection biases of baseline covariates between groups.9,10 The cohorts were matched for propensity scores at a 1:1 ratio with a caliper of 0.02. The confounding factors included in the model were age, race, tumor size, and marital status. Before PSM, quantitative data were analyzed by the student’s t test or the Mann–Whitney U test, while qualitative data were compared using the $\chi^2$ test or Fisher’s exact probability test, as appropriate. After PSM, the matched groups were compared using a paired t-test or Wilcoxon signed test for continuous variables and the McNemar test for categorical data. A two-sided p value of less than 0.05 was considered as statistically significant. All the analyses were conducted using SPSS version 26.0 and R software version 3.6.2.

3 | RESULTS

3.1 | Baseline characteristics

A total of 1066 patients were enrolled in this study between 1975 and 2016. The baseline characteristics of all patients and the comparison of CHC and ICC patients are summarized in Table 1. Among the patients, 286 and 780 patients were in the CHC and ICC cohorts, respectively. The clinicopathological features in Table 1 were significantly different except for the marital status, combined metastasis in the brain, and whether or not the patient received radiation. The CHC group included a larger proportion of men (73.1% vs. 26.9%) and had a majority of White ethnicity (71.3%, 204/286). The mean age of the CHC cohort was 62.8 ± 10.7 years old, which was significantly younger than the ICC cohort ($p < 0.001$). The patients in the CHC group showed a distinctly higher incidence of elevated AFP levels compared to the patients in the ICC group (53.5% vs. 17.7%, $p < 0.001$). Notably, the rate of liver fibrosis was significantly higher in CHC patients (12.2% vs. 3.8%, $p < 0.001$). A large proportion of CHC patients were diagnosed at early stages (stage I and II: 56.6%). Of the patients, 52.8% (151/286) underwent surgery and 42.0% (120/286) underwent chemotherapy in the CHC cohort. Detailed data are presented in Table 1.
### Table 1: Baseline characteristics of CHC and ICC patients

| Variables                  | All patients (n = 1066) | CHC (n = 286) | ICC (n = 780) | p value |
|----------------------------|-------------------------|---------------|---------------|---------|
| **Gender**                 |                         |               |               | <0.001  |
| Male                       | 594 (55.7%)             | 209 (73.1%)   | 385 (49.4%)   |         |
| Female                     | 472 (44.3%)             | 77 (26.9%)    | 395 (50.6%)   |         |
| **Age (years), ±SD**       | 62.8 ± 11.4             | 60.8 ± 10.7   | 63.6 ± 11.6   | <0.001  |
| **Race**                   |                         |               |               | <0.001  |
| Black                      | 100 (9.4%)              | 29 (10.1%)    | 71 (9.1%)     |         |
| White                      | 835 (78.3%)             | 204 (71.3%)   | 631 (80.9%)   |         |
| Other                      | 131 (12.3%)             | 53 (18.5%)    | 78 (10.0%)    |         |
| **Tumor size (cm), ±SD**   | 7.02 ± 4.00             | 6.24 ± 4.32   | 7.30 ± 3.84   | <0.001  |
| **Marital status**         |                         |               |               | 0.608   |
| Married                    | 620 (58.2%)             | 170 (59.4%)   | 450 (57.7%)   |         |
| Other                      | 446 (41.8%)             | 116 (40.6%)   | 330 (42.3%)   |         |
| **AFP level**              |                         |               |               | <0.001  |
| Positive                   | 291 (27.3%)             | 153 (53.5%)   | 138 (17.7%)   |         |
| Negative                   | 366 (34.3%)             | 75 (26.3%)    | 291 (37.3%)   |         |
| Borderline                 | 2 (0.2%)                | 1 (0.3%)      | 1 (0.1%)      |         |
| Unknown                    | 407 (38.2%)             | 57 (19.9%)    | 350 (44.9%)   |         |
| **Fibrosis**               |                         |               |               | <0.001  |
| Severe or cirrhosis        | 65 (6.1%)               | 35 (12.2%)    | 30 (3.8%)     |         |
| None or unknown            | 1001 (93.9%)            | 251 (87.8%)   | 750 (96.2%)   |         |
| **Grade**                  |                         |               |               | <0.001  |
| Well                       | 47 (4.4%)               | 11 (3.8%)     | 36 (4.6%)     |         |
| Moderately                 | 298 (28.0%)             | 63 (22.0%)    | 235 (30.1%)   |         |
| Poorly                     | 289 (27.1%)             | 108 (37.8%)   | 181 (23.2%)   |         |
| Undifferentiated           | 11 (1.0%)               | 8 (2.8%)      | 3 (0.4%)      |         |
| Unknown                    | 421 (39.5%)             | 96 (33.6%)    | 325 (41.7%)   |         |
| **T stage**                |                         |               |               | <0.001  |
| T1                         | 417 (39.1%)             | 109 (38.1%)   | 308 (39.4%)   |         |
| T2                         | 202 (18.9%)             | 89 (31.2%)    | 113 (14.5%)   |         |
| T3                         | 337 (31.6%)             | 69 (24.1%)    | 268 (34.4%)   |         |
| T4                         | 91 (8.5%)               | 17 (5.9%)     | 74 (9.5%)     |         |
| TX                         | 19 (1.8%)               | 2 (0.7%)      | 17 (2.2%)     |         |
| **N stage**                |                         |               |               | 0.001   |
| N0                         | 808 (75.8%)             | 240 (83.9%)   | 568 (72.8%)   |         |
| N1                         | 214 (20.1%)             | 39 (13.7%)    | 175 (22.5%)   |         |
| NX                         | 44 (4.1%)               | 7 (2.4%)      | 37 (4.7%)     |         |
| **M stage**                |                         |               |               | 0.013   |
| M0                         | 783 (73.5%)             | 226 (79.0%)   | 557 (71.4%)   |         |
| M1                         | 283 (26.5%)             | 60 (21.0%)    | 223 (28.6%)   |         |
| **AJCC stage**             |                         |               |               | <0.001  |
| I                          | 307 (28.8%)             | 90 (31.4%)    | 217 (27.8%)   |         |
| II                         | 144 (13.5%)             | 72 (25.2%)    | 72 (9.2%)     |         |
| IIIA                       | 162 (15.2%)             | 34 (11.9%)    | 128 (16.4%)   |         |
| IIIB                       | 41 (3.8%)               | 10 (3.5%)     | 31 (4.0%)     |         |

(Continues)
3.2 | Survival outcomes

Of all the enrolled patients, the OS and cancer-specific survival (CSS) were significantly better in the CHC group than in the ICC group. (Figure 1) The 1-year, 3-year, and 5-year OS probabilities were 47.1%, 25.7%, and 21.3% in the CHC group and 46.4%, 19.6%, and 13.8% in the ICC group, respectively. The 1-year, 3-year, and 5-year CSS probabilities were 52.1%, 30.5%, and 26.9% in the CHC group and 49.2%, 22.3%, and 16.3% in the ICC group, respectively. The 1-year OS and CSS were comparable between the two groups ($p > 0.05$). Additionally, the 3-year and 5-year OS and CSS were significantly lower in the ICC group than in the CHC group ($p < 0.05$). (Table 2) Further landmark analysis of all patients in the first 36 months of treatment showed no significant difference in the OS between the CHC and ICC groups. However, the similarity in the OS of CHC patients compared to ICC patients within 36 months was lost at the subsequent follow-up. (Figure 2) In other words, an OS rate estimate of less than 3 years might not be sufficient to evaluate the long-term clinical outcomes in patients with CHC.

3.3 | Overall survival of CHC and ICC patients at different stages

The OS rates of CHC patients at any stage were not significantly different from those of ICC patients at the
corresponding stage ($p > 0.05$). (Figure 3) However, landmark analyses to access the OS probabilities by dividing the entire follow-up period into the initial 3 years and the subsequent years revealed different patterns.

### 3.4 Treatment patterns and the relative survival outcomes in CHC patients

The treatment patterns of the different stages are summarized in Table 3. Surgery and chemotherapy remained the main treatment options, whereas radiation was rarely performed in the CHC cohort. The majority of early stage patients (stage I and II) underwent surgery and were associated with a better OS than other treatment options in the CHC group ($p < 0.001$). As for the advanced stages (stages III and IV), surgery also demonstrated more favorable OS outcomes compared with nonsurgical modalities ($p < 0.001$, Figure 4).

### 3.5 Overall survival of CHC patients with different surgical types

Of all the patients in the CHC group, 106 patients underwent hepatic resection (HR) and 45 patients underwent liver transplantation (LT). Notably, patients who underwent HR tended to be older ($60.58 \pm 9.62$ vs. $55.87 \pm 9.71$, $p = 0.007$) and had a larger tumor size ($6.14 \pm 3.66$ cm vs. $3.12 \pm 2.07$ cm, $p < 0.001$). In addition, marital status and race differed significantly between the two groups. Except for these remarkably different characteristics, the remaining baseline demographic data did not show statistical differences (Table 4); after propensity score matching (PSM), 29 patients were identified in each matched cohort, and the baseline parameters were well balanced. (Table 4) The long-term outcomes were compared between the HR and LT groups by evaluating the OS before and after PSM. The OS probabilities were significantly different between the two unmatched cohorts ($p = 0.016$), while in the matched group, the OS rates were comparable regardless of the surgical type ($p = 0.440$, Figure 5).

### 3.6 Analysis of prognostic factors for survival outcomes

Univariate analysis of all CHC patients revealed that the age at diagnosis, tumor size, T stage ($T_3$, $T_x$), N stage ($N_1$, $N_X$), M$_1$ stage, advanced AJCC stage (IIIC, IV), lung metastasis, surgical intervention, and chemotherapy were the risk factors for OS. On multivariate Cox regression

| Outcomes          | CHC ($n = 286$) | ICC ($n = 780$) | $p$ value |
|-------------------|----------------|----------------|-----------|
| Overall survival  |                |                |           |
| 1-year            | 47.1%          | 46.4%          | 0.421     |
| 3-year            | 25.7%          | 19.6%          | **0.024** |
| 5-year            | 21.3%          | 13.8%          | $<0.001$  |
| Cancer-specific survival | | | |
| 1-year            | 52.1%          | 49.2%          | 0.203     |
| 3-year            | 30.5%          | 22.3%          | **<0.001** |
| 5-year            | 26.9%          | 16.3%          | **<0.001** |

Bold values indicate $p < 0.05$.

Abbreviations: CHC, combined hepatocellular-cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma.
analysis, only the tumor size (hazard ratio [HR] 1.01; 95% CI 1.00–1.01; \( p = 0.020 \)), M1 stage (HR, 1.63; 95% CI, 1.04–2.56; \( p = 0.033 \)), AJCC stage IIIA (HR 2.27; 95% CI 1.22–4.24, \( p = 0.010 \)), AJCC stage IVA (HR 2.41; 95% CI 1.47–3.97, \( p = 0.001 \)), surgery (HR 0.29; 95% CI 0.20–0.43, \( p < 0.001 \)), and chemotherapy (HR 0.64; 95% CI 0.44–0.94; \( p = 0.024 \)) were significantly associated with the OS. With respect to cancer-specific survival (CSS), a multivariate analysis
YANG and SHI identified that the tumor size (HR 1.01; 95% CI 1.00–1.01; p = 0.022), T4 (HR 2.34; 95% CI 1.15–4.74, p = 0.019), M1 (HR 1.91; 95% CI 1.20–3.03, p = 0.006), AJCC stage IV (HR 2.64; 95% CI 1.56–4.47, p < 0.001), and surgical intervention (HR 0.29; 95% CI 0.19–0.43, p < 0.001) were the independent predictors of CSS. (Table 5).

### DISCUSSION

The current study showed that CHC was associated with better long-term survival outcomes compared with ICC. Surgery and chemotherapy play an increasingly vital role in prolonging the survival. Although the OS rates were comparable at any stage between patients with CHC and ICC, the total OS rates were better in the CHC group. One explanation may be that a large proportion of CHC patients were diagnosed at an early stage.

Containing unequivocal components of both biliary and hepatocellular differentiation, CHC, first reported in 1903, was accompanied by growing clinical concerns due to its distinct clinicopathological features. The latest 2019 WHO classification streamlined its previous histological classification system; additionally, the new edition emphasized CHC simply as a mixed tumor with intimate intermingling elements of HCC and ICC. Notably, the proportion of these two different components was not immutably fixed and invariable, and might be correlated with radiographic as well as physiological features. As a result, the diverse histological characteristics have led to difficulties in accurate diagnosis and posed challenges in therapy.

Till date, the histogenesis of CHC remains controversial, although some related theories have been proposed. Recent evidence has shown that hepatic progenitor cells (HPCs), which reside in the biliary ductules, have the potential to differentiate into hepatic or biliary cells. Thus, several investigators have speculated that CHC may be derived from HPCs.

The American Joint Committee on Cancer (AJCC) 8th edition of TNM staging classified CHC and ICC into one category and shared the ICC-specific staging system. The AJCC staging systems have been revised several times; however, until recently, the CHC did not own specific protocol. Tian et al. constructed a risk prediction model based on the clinical parameters to preoperatively discriminate CHC from HCC or ICC and to tailor the optimal treatment.

Are the clinical and pathological features of patients with CHC identical to those of patients with ICC? The
TABLE 4 Demographic and clinical characteristics of patients undergoing HR or LT before and after PSM

| Variables          | Before PSM | After PSM |
|--------------------|------------|-----------|
|                    | HR (n = 106) | LT (n = 45) | p value | HR (n = 29) | LT (n = 29) | p value |
| Gender             | 0.375      |           |         | 1.00       |           |         |
| Male               | 75 (70.8%) | 35 (77.8%) |         | 21 (72.4%) | 22 (75.9%) |         |
| Female             | 31 (29.2%) | 10 (22.2%) |         | 8 (27.6%)  | 7 (24.1%)  |         |
| Age (years), ±SD   | 60.58 ± 9.62 | 55.87 ± 9.71 | 0.007  | 60.52 ± 10.61 | 58.41 ± 6.86 | 0.245 |
| Race               | 0.033      |           |         | 0.343      |           |         |
| Black              | 7 (6.6%)   | 5 (11.1%)  |         | 3 (10.3%)  | 1 (3.4%)   |         |
| White              | 73 (68.9%) | 37 (82.2%) |         | 20 (69.0%) | 25 (86.3%) |         |
| Other              | 26 (24.5%) | 3 (6.7%)   |         | 6 (20.7%)  | 3 (10.3%)  |         |
| Tumor size (cm), ±SD | 6.14 ± 3.66 | 3.12 ± 2.07 | <0.001 | 3.78 ± 2.71 | 3.53 ± 2.31 | 0.467 |
| Marital status     | 0.014      |           |         | 1.00       |           |         |
| Married            | 72 (67.9%) | 21 (46.7%) |         | 12 (41.4%) | 11 (37.9%) |         |
| Other              | 34 (32.1%) | 24 (53.3%) |         | 17 (58.6%) | 18 (62.1%) |         |
| AFP level          | 0.592      |           |         | 0.684      |           |         |
| Positive           | 58 (54.8%) | 20 (44.5%) |         | 13 (44.8%) | 15 (51.7%) |         |
| Negative           | 26 (24.5%) | 14 (31.1%) |         | 10 (34.5%) | 7 (24.1%)  |         |
| Borderline         | 1 (0.9%)   | 0         |         | 1 (3.4%)   | 0         |         |
| Unknown            | 21 (19.8%) | 11 (24.4%) |         | 5 (17.2%)  | 7 (24.1%)  |         |
| Fibrosis           | 0.722      |           |         | 0.238      |           |         |
| Severe or cirrhosis| 14 (13.2%) | 5 (11.1%)  |         | 7 (24.1%)  | 4 (13.8%)  |         |
| None or unknown    | 92 (86.8%) | 40 (88.9%) |         | 22 (75.9%) | 25 (86.2%) |         |
| Grade              | 0.402      |           |         | 0.503      |           |         |
| Well               | 3 (2.8%)   | 2 (4.4%)   |         | 0         | 1 (3.4%)   |         |
| Moderately         | 28 (26.4%) | 17 (37.8%) |         | 7 (24.1%)  | 11 (34.0%) |         |
| Poorly             | 46 (43.5%) | 13 (28.9%) |         | 10 (34.5%) | 10 (34.5%) |         |
| Undifferentiated   | 5 (4.7%)   | 1 (2.2%)   |         | 2 (6.9%)   | 1 (3.4%)   |         |
| Unknown            | 24 (22.6%) | 12 (26.7%) |         | 10 (34.5%) | 6 (20.7%)  |         |
| T stage            | 0.182      |           |         | 0.060      |           |         |
| T1                 | 46 (43.4%) | 17 (37.8%) |         | 17 (58.7%) | 7 (24.1%)  |         |
| T2                 | 34 (32.1%) | 22 (48.9%) |         | 9 (31.0%)  | 16 (55.3%) |         |
| T3                 | 18 (17.0%) | 5 (11.1%)  |         | 2 (6.9%)   | 5 (17.2%)  |         |
| T4                 | 8 (7.5%)   | 1 (2.2%)   |         | 1 (3.4%)   | 1 (3.4%)   |         |
| N stage            | 0.579      |           |         | 0.237      |           |         |
| N0                 | 96 (90.6%) | 42 (93.3%) |         | 29 (100%)  | 26 (89.7%) |         |
| N1                 | 10 (9.4%)  | 3 (6.7%)   |         | 0         | 3 (10.3%)  |         |
| M stage            | 0.608      |           |         | 1.00       |           |         |
| M0                 | 99 (93.4%) | 43 (95.6%) |         | 28 (96.6%) | 27 (93.1%) |         |
| M1                 | 7 (6.6%)   | 2 (4.4%)   |         | 1 (3.4%)   | 2 (6.9%)   |         |
| AJCC stage         | 0.405      |           |         | 0.450      |           |         |
| I                  | 44 (41.5%) | 17 (37.8%) |         | 17 (58.7%) | 7 (24.1%)  |         |
| II                 | 30 (28.3%) | 19 (42.3%) |         | 8 (27.6%)  | 13 (44.9%) |         |
| IIIA               | 11 (10.4%) | 5 (11.1%)  |         | 2 (6.9%)   | 5 (17.2%)  |         |
| IIIB               | 5 (4.7%)   | 0         |         | 1 (3.4%)   | 0         |         |
| IIIIC              | 9 (8.5%)   | 2 (4.4%)   |         | 0         | 2 (6.9%)   |         |
| IV                 | 7 (6.6%)   | 2 (4.4%)   |         | 1 (3.4%)   | 2 (6.9%)   |         |

Bold values indicate \( p < 0.05 \).

Abbreviations: AJCC, American joint committee on cancer; HR, hepatic resection; LT, liver transplantation; PSM, propensity score matching; SD, standard deviation.
answer in the current large population-based study was “No.” Unlike some previous studies, the baseline characteristics regarding the sex ratio, age at diagnosis, tumor grade and stage, and distant metastasis were significantly different between the two groups. Notably, CHC patients were associated with a high incidence of underlying liver cirrhosis and elevated AFP level in comparison with ICC patients, which was in accordance with previous findings. However, subsequent studies found that the background of liver cirrhosis was not sufficient and was a prerequisite condition for the occurrence of CHC. Due to the overlapping imaging features of both HCC and ICC, a misdiagnosis often occurs in CHC patients. Li et al. proposed that combining elevation or discordance of the AFP level with incompatible imaging features of HCC may lead to a diagnosis of CHC. The distinction between CHC and HCC or ICC may largely depend on the composition ratio.

Surgical resection remains the cornerstone of curative treatment for patients with CHC. In the current study, surgery yielded better survival benefits than any other treatment option in the early stages. As for patients at advanced stages, curative resection was still associated with favorable outcomes compared with non-surgery. However, both CHC and ICC are regarded as more aggressive malignancies with a worse prognosis than HCC. The 3-year and 5-year OS rates were relatively lower than those of HCC reported in previous findings. Although there was no significant between-group difference in the OS rate, the patients in the ICC group, as compared with those in the CHC group, exhibited a significant reduction in the OS rate after the initial 36 months following treatments. Considering the regional lymphadenopathy features caused by the biliary cellular component, aggressive surgical intervention, including major hepatectomy and lymphadenectomy, may improve the poor prognosis of CHC patients. The role of lymph node dissection in survival benefits remains a matter of discussion. In our study, a multivariate analysis in the CHC group revealed that the lymph node status was not an independent risk factor for the OS or CSS. Similarly, the survival benefit of LT remains controversial. It is generally believed that transplantation for CHC patients conferred comparable survival benefits to hepatectomy, albeit inferior to HCC, although there are limited data to substantiate the validity. Using a propensity score matching analysis, our study revealed that the long-term outcomes of selected patients with CHC were comparable following HR or LT, which was consistent with previous findings. The standard scheme for systemic chemotherapy remains unclear. CHC patients were more frequently treated according to the treatment strategies for HCC or ICC. Further investigation is warranted to establish a standard regimen for CHC.

Our study had several limitations that should be acknowledged. First, inherent selection biases were unavoidable owing to the retrospective design. Second, the absence of detailed information, such as underlying liver diseases, tumor markers, pathologic features, and progression-free survival in the SEER database hampered the execution of more specific analyses. Finally, the diagnostic criteria for CHC may be inconsistent because of the varied pathological classifications.

Despite these limitations, our data demonstrated that CHC, as a rare malignancy of the liver, was associated with a similar OS in the initial 36 months, while a better survival in the subsequent follow-up compared with ICC. Furthermore, surgical intervention could significantly
### TABLE 5  
Univariate and multivariate analyses for overall survival and cancer-specific survival in CHC patients

| Variables | Overall survival | Cancer-specific survival |
|-----------|-----------------|-------------------------|
|           | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|           | HR (95% CI) | p value | HR (95% CI) | p value |
| Age       | 1.02 (1.00–1.03) | **0.027** | 1.00 (0.99–1.02) | 0.885 |
|           | 1.02 (1.00–1.03) | **0.022** | 1.01 (0.99–1.02) | 0.411 |
| Sex       |                |            |                |            |
| Female    | Ref            |            | Ref            |            |
| Male      | 1.20 (0.86–1.67) | 0.296      | 1.14 (0.80–1.63) | 0.480      |
| Race      |                |            |                |            |
| Black     | Ref            |            | Ref            |            |
| White     | 0.86 (0.53–1.40) | 0.553      | 0.97 (0.56–1.65) | 0.899      |
| Other     | 0.80 (0.46–1.41) | 0.444      | 0.88 (0.47–1.65) | 0.690      |
| Tumor size| 1.01 (1.00–1.01) | <**0.001** | 1.01 (1.00–1.01) | **0.020** |
| Machri status |                |            |                |            |
| Married   | Ref            |            | Ref            |            |
| Other     | 1.20 (0.90–1.61) | 0.210      | 1.15 (0.84–1.58) | 0.380      |
| AFP level |                |            |                |            |
| Negative  | Ref            |            | Ref            |            |
| Borderline| 0.48 (0.06–3.24) | 0.426      | 0.01 (0.01-4E+154) | 0.953      |
| Positive  | 0.90 (0.64–1.26) | 0.532      | 0.83 (0.58–1.19) | 0.316      |
| Unknown   | 0.81 (0.53–1.25) | 0.340      | 0.85 (0.54–1.33) | 0.469      |
| Fibrosis  |                |            |                |            |
| None or unknown | Ref |            | Ref            |            |
| Severe or cirrhosis | 1.04 (0.66–1.62) | 0.877      | 1.09 (0.68–1.74) | 0.718      |
| Grade     |                |            |                |            |
| Well      | Ref            |            | Ref            |            |
| Moderately| 0.66 (0.29–1.49) | 0.312      | 0.57 (0.25–1.31) | 0.183      |
| Poorly    | 1.48 (0.68–3.22) | 0.318      | 1.26 (0.58–2.74) | 0.565      |
| Undifferentiated | 0.92 (0.29–2.90) | 0.887      | 0.72 (0.21–2.47) | 0.603      |
| Unknown   | 1.12 (0.51–2.44) | 0.779      | 0.95 (0.43–2.09) | 0.896      |
| T stage   |                |            |                |            |
| T1        | Ref            |            | Ref            |            |
| T2        | 1.14 (0.81–1.61) | 0.451      | 1.14 (0.77–1.67) | 0.516      |
| T3        | 1.95 (1.33–2.84) | **0.001** | 2.26 (1.51–3.38) | <**0.001** |
|           | 1.33 (0.90–1.98) | 0.157      | 1.58 (0.98–2.54) | 0.063      |
| Variables          | Overall survival | Cancer-specific survival |
|-------------------|------------------|-------------------------|
|                   | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|                   | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value |
| T4                | 1.76 (0.93–3.35) | 0.083 | 1.88 (0.94–3.76) | 0.072 | 2.15 (1.12–4.13) | 0.021 | 2.34 (1.15–4.74) | 0.019 |
| TX                | 18.0 (2.38–136.4) | **0.005** | 4.48 (0.44–45.94) | 0.207 | 23.0 (3.00–176.65) | **0.003** | 6.56 (0.59–72.43) | 0.125 |
| N stage           |                  |        |                |        |                  |        |                |        |
| N0                | Ref             |        |                |        |                  |        |                |        |
| N1                | 2.02 (1.35–3.04) | **0.001** | 1.19 (0.74–1.92) | 0.462 | 1.97 (1.27–3.06) | **0.002** | 0.97 (0.59–1.62) | 0.912 |
| NX                | 4.55 (1.84–11.25) | **0.001** | 1.36 (0.46–4.06) | 0.577 | 4.14 (1.51–11.35) | **0.006** | 0.91 (0.26–3.11) | 0.875 |
| M stage           |                  |        |                |        |                  |        |                |        |
| M0                | Ref             |        |                |        |                  |        |                |        |
| MI                | 2.74 (1.92–3.91) | **<0.001** | 1.63 (1.04–2.56) | **0.033** | 3.18 (2.20–4.59) | **<0.001** | 1.91 (1.20–3.03) | **0.006** |
| AJCC stage        |                  |        |                |        |                  |        |                |        |
| I                 | Ref             |        |                |        |                  |        |                |        |
| II                | 1.08 (0.73–1.59) | 0.703 | 1.25 (0.84–1.87) | 0.271 | 1.05 (0.69–1.63) | 0.802 | 1.21 (0.77–1.89) | 0.402 |
| IIIA              | 1.58 (0.96–2.62) | 0.074 | 1.54 (0.89–2.69) | 0.126 | 1.84 (1.08–3.12) | **0.024** | 1.65 (0.92–2.96) | 0.093 |
| IIIB              | 1.51 (0.65–3.50) | 0.343 | 1.41 (0.58–3.45) | 0.447 | 1.85 (0.79–4.34) | 0.159 | 1.72 (0.69–4.24) | 0.242 |
| IIIC              | 2.24 (1.26–3.98) | **0.006** | 2.27 (1.22–4.24) | **0.010** | 1.98 (1.02–3.84) | **0.044** | 1.87 (0.92–3.82) | 0.084 |
| IV                | 3.25 (2.15–4.92) | **<0.001** | 2.41 (1.47–3.97) | **0.001** | 3.83 (2.47–5.92) | **<0.001** | 2.64 (1.56–4.47) | **<0.001** |
| Combined Mets at brain | NA          | NA         |                |        |                  |        |                |        |
| Combined Mets at bone | 2.42 (0.77–7.63) | 0.132 | 2.74 (0.87–8.67) | 0.086 |                  |        |                |        |
| Combined Mets at lung | 4.24 (1.97–9.14) | **<0.001** | 1.57 (0.63–3.92) | 0.334 | 4.92 (2.27–10.65) | **<0.001** | 1.64 (0.66–4.05) | 0.287 |
| Surgery           |                  |        |                |        |                  |        |                |        |
| None              | Ref             |        |                |        |                  |        |                |        |
| Done              | 0.30 (0.22–0.40) | **<0.001** | 0.29 (0.20–0.43) | **<0.001** | 0.27 (0.20–0.38) | **<0.001** | 0.29 (0.19–0.43) | **<0.001** |
| Radiation         |                  |        |                |        |                  |        |                |        |
| None              | Ref             |        |                |        |                  |        |                |        |
| Done              | 1.02 (0.45–2.29) | 0.970 |                  |        | 1.19 (0.53–2.69) | 0.680 |                  |        |
| Chemotherapy      |                  |        |                |        |                  |        |                |        |
| None/unknown      | Ref             |        |                |        |                  |        |                |        |
| Done              | 0.65 (0.49–0.87) | **<0.001** | 0.64 (0.44–0.94) | **0.024** | 0.58 (0.42–0.79) | **0.001** | 0.66 (0.43–1.02) | 0.063 |

Bold values indicate p < 0.05.

Abbreviations: AJCC, American joint committee on cancer; CHC, combined hepatocellular-cholangiocarcinoma; CI, confidence interval; HR, hazard ratio; Mets, metastasis; NA, not applicable; Ref, reference.
improve the prognosis in the early stages. For advanced stages, surgery may be the optimal option.

ACKNOWLEDGMENTS
The authors would like to appreciate the NCI for open access to the Surveillance, Epidemiology, and End Results (SEER) database.

CONFLICT OF INTEREST
No conflict of interest was declared by the authors.

AUTHOR CONTRIBUTION
Guangjun Shi contributed to the conception and collected data. Zhen Yang designed the study and wrote the manuscript.

ETHICAL STATEMENT
Ethical approval was not sought from institutional review board (IRB) because of the de-identified data and the nature of the present study. And on account of the retrospective study design, the requirements for informed consent were waived off.

DATA AVAILABILITY STATEMENT
The raw data supporting the present study will be available from the corresponding author upon reasonable request.

ORCID
Zhen Yang https://orcid.org/0000-0002-6177-1883
Guangjun Shi https://orcid.org/0000-0002-6926-2354

REFERENCES
1. Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology (Baltimore, MD). 2018;68(1):113-126.
2. Akiba J, Nakashima O, Hattori S, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol. 2013;37(4):496-505.
3. Ramai D, Ofosu A, Lai JK, Reddy M, Adler DG. Combined hepatocellular cholangiocarcinoma: a population-based retrospective study. Am J Gastroenterol. 2019;114(9):1496-1501.
4. Kim TH, Kim H, Joo I, Lee JM. Combined hepatocellular-cholangiocarcinoma: changes in the 2019 World Health Organization histological classification system and potential impact on imaging-based diagnosis. Korean J Radiol. 2020;21(10):1115-1125.
5. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188.
6. Chok KS, Ng KK, Cheung TT, et al. An update on long-term outcome of curative hepatic resection for hepatoceli-cholangiocarcinoma. World J Surg. 2009;33(9):1916-1921.
7. Cazals-Hatem D, Rebouissou S, Boulac-Sage P, et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol. 2004;41(2):292-298.
8. Joseph NM, Tsokos CG, Umetsu SE, et al. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol. 2019;248(2):164-178.
9. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.
10. Kane LT, Fang T, Galetta MS, et al. Propensity score matching: a statistical method. Clin Spine Surg. 2020;33(3):120-122.
11. Sciarra A, Park YN, Sempoux C. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma. Hum Pathol. 2020;96:48-55.
12. Wang AQ, Zheng YC, Du J, et al. Combined hepatocellular cholangiocarcinoma: controversies to be addressed. World J Gastroenterol. 2016;22(18):4459-4465.
13. Shibahara J, Hayashi A, Misumi K, et al. Clinicopathologic characteristics of hepatocellular carcinoma with reactive Ductule-like components, a subset of liver cancer currently classified as combined hepatocellular-cholangiocarcinoma with stem-cell features. Typical subtype. Am J Surg Pathol. 2016;40(5):608-616.
14. Wakizaka K, Yokoo H, Kamiyama T, et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol. 2019;34(6):1074-1080.
15. Zhao Q, Yu WL, Lu XY, et al. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study. Chinese J Cancer. 2016;35(1):82.
16. Sasaki M, Sato Y, Nakamura Y. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology. 2017;70(3):423-434.
17. Couluoan C, Cavard C, Rubbia-Brandt L, et al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways. Carcinogenesis. 2012;33(9):1791-1796.
18. Sasaki M, Sato H, Kakuda Y, Sato Y, Choi JH, Nakamura Y. Clinicopathological significance of 'subtypes with stem-cell feature' in combined hepatocellular-cholangiocarcinoma. Liver Int. 2015;35(3):1024-1035.
19. Ikeda H, Harada K, Sato Y, et al. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol. 2013;140(3):329-340.
20. Liao X, Zhang D. The 8th Edition American Joint Committee on cancer staging for hepatopancreato-biliary cancer: a review and update. Arch Pathol Lab Med. 2021;145(5):543-553. https://doi.org/10.5888/apra.2020-0032-RA
21. Tian MX, He WJ, Liu WR, et al. A novel risk prediction model for patients with combined hepatocellular-cholangiocarcinoma. J Cancer. 2018;9(6):1025-1032.
22. Schizas D, Mastoraki A, Routsi E, et al. Combined hepatocellular-cholangiocarcinoma: an update on epidemiology, classification, diagnosis and management. HBPD Int. 2020;19(6):515-523.
23. Komuta M, Yeh MM. A review on the update of combined hepatocellular cholangiocarcinoma. Semin Liver Dis. 2020;40(2):124-130.
24. Sagrini E, Iavarone M, Stefanini F, et al. Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. *United European Gastroenterol J*. 2019;7(1):69-77.

25. Yang J, Zhang YH, Li JW, et al. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *World J Gastroenterol*. 2020;26(46):7325-7337.

26. Li R, Yang D, Tang CL, et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. *BMC Cancer*. 2016;16:158.

27. Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. *Am J Surg*. 2005;189(1):120-125.

28. Lee WS, Lee KW, Heo JS, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Surg Today*. 2006;36(10):892-897.

29. Tao CY, Liu WR, Jin L, et al. Surgical treatment of combined hepatocellular-cholangiocarcinoma is as effective in elderly patients as it is in younger patients: a propensity score matching analysis. *J Cancer*. 2018;9(6):1106-1112.

30. Ercolani G, Grazi GL, Ravaiolli M, et al. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy. *Ann Surg*. 2004;239(2):202-209.

31. Panjala C, Senecal DL, Bridges MD, et al. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. *Am J Transplant*. 2010;10(5):1263-1267.

32. Jung DH, Hwang S, Song GW, et al. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection. *Liver Transplant*. 2017;23(3):330-341.

33. Groeschl RT, Turaga KK, Gamblin TC. Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. *J Surg Oncol*. 2013;107(6):608-612.

34. Rogers JE, Bolonesi RM, Rashid A, et al. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. *J Gastrointest Oncol*. 2017;8(2):347-351.

35. Kobayashi S, Terashima T, Shiba S, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable hepatocellular and cholangiocarcinoma. *Cancer Sci*. 2018;109(8):2549-2557.

36. Liao X, Zhang D. The 8th Edition American Joint Committee on cancer staging for hepatopancreatobiliary cancer: a review and update. Arch Pathol Lab Med. 2021.145(5):543–553. DOI:10.5858/arpa.2020-0032-RA.

**How to cite this article:** Yang Z, Shi G. Survival outcomes of combined hepatocellular-cholangiocarcinoma compared with intrahepatic cholangiocarcinoma: A SEER population-based cohort study. *Cancer Med*. 2022;11:692–704. doi:10.1002/cam4.4474